Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Future Oncology (London, England)|February 13, 2015
Three-tiered nodal classification system for bladder cancer: a new proposalJose A Pedrosa, Michael O Koch, Hristos Z Kaimakliotis, et al.
Urologic Oncology|June 24, 2014
Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?Hristos Z Kaimakliotis, M Francesca Monn, K Clint Cary, et al.
Journal of Endourology|April 27, 2017
Preoperative Nomograms for Predicting Renal Function at 1 Year After Partial NephrectomyCheuk Fan Shum, Clinton D Bahler, Clint Cary, et al.
Future Oncology (London, England)|June 4, 2016
Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histologyHristos Z Kaimakliotis, M Francesca Monn, Jane S Cho, et al.
Urologic Oncology|August 18, 2015
Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary seriesNick W Liu, Kashyap Shatagopam, M Francesca Monn, et al.
European Urology|March 18, 2014
Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trialCheryl T Lee, Sam S Chang, Ashish M Kamat, et al.
Scandinavian Journal of Urology|May 14, 2020
Robotic and open partial nephrectomy for intermediate and high complexity tumors: a matched-pairs comparison of surgical outcomes at a single institutionZain A Abedali, M Francesca Monn, Patrick Huddleston, et al.
Urologic Oncology|September 13, 2015
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activityNoah M Hahn, Beatrice S Knudsen, Siamak Daneshmand, et al.
Clinical Genitourinary Cancer|January 2, 2017
Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant ChemotherapyDerek E Thomas, Hristos Z Kaimakliotis, Kevin R Rice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2016
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157Noah M Hahn, Trinity J Bivalacqua, Ashley E Ross, et al.
Pageof 7